Global pharmaceutical company Eli Lilly (NYSE:LLY ... beating analysts’ expectations by 3%, and Johnson & Johnson reported revenues up 5.3%, in line with consensus estimates.
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly and Co., Amgen and Bristol Myers Squibb — due to announce results. Johnson & Johnson and AbbVie have already reported with both beating estimates for both earnings and sales.
Recent health news highlights a range of developments from Uganda discharging Ebola patients to drugmakers seeking safer ...
Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to severely active Crohn's disease receiving two years of continuous treatment ...
JSO Sheriff T.K. Waters and officers walked through neighborhoods on the Southside to hear the concerns of the community. Read full article: Woman dies after crawling through a pickup truck window ...
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect.
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results